Consensus Nektar Therapeutics

Equities

NKTR

US6402681083

Real-time Estimate Cboe BZX Other stock markets 01:47:57 2024-04-18 pm EDT			5-day change	1st Jan Change
1.295 ^USD	-4.07%		-18.04%	+129.20%

Mar. 19	Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	CI
Mar. 05	Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata	MT

Evolution of the average Target Price on Nektar Therapeutics

Price target over the last 5 years

History of analyst recommendation changes

39d6.Q1wunVAAU1NBvQq1sizGo0UTOmYLyDZqEZszcsPel88.BDJYrTZ1Fx0w83yH0B-ixCR6YCxG_3kEZM52MIuT4aUOD3mlaF8XECrfbQ~0cfc1d888f4c91b80b7a8da6c61d0bbe

Analyst Recommendations on Nektar Therapeutics

Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating	Mar. 05	MT
TD Cowen Upgrades Nektar Therapeutics to Outperform From Market Perform	Nov. 09	MT
Nektar Therapeutics Says Corrected Data From Studies of Eczema Drug Showed 83% Improvement Rate; Shares Jump	23-08-07	MT
Jefferies Upgrades Nektar Therapeutics to Hold From Underperform, Adjusts Price Target to $1 From $1.50	23-05-10	MT
Oppenheimer Adjusts Nektar Therapeutics Price Target to $3 From $5, Maintains Perform Rating	23-03-06	MT
Goldman Sachs Adjusts Price Target on Nektar Therapeutics to $2 From $3, Maintains Sell Rating	23-02-27	MT
Jefferies Downgrades Nektar Therapeutics to Underperform From Hold, Adjusts Price Target to $1.50 From $3.20	23-02-24	MT
SVB Securities Adjusts Price Target on Nektar Therapeutics to $3 From $5, Keeps Market Perform Rating	23-02-24	MT
FTSE 100 Falls as Jobs Data Fuel BOE Rate Rise Bets	22-10-11	DJ
JPMorgan Downgrades Nektar Therapeutics to Underweight From Neutral	22-08-08	MT
Jefferies & Co. Assumes Nektar Therapeutics at Hold, Adjust Price Target to $4 From $12	22-05-31	MT
Oppenheimer Adjusts Nektar Therapeutics Price Target to $5 From $6, Maintains Perform Rating	22-04-20	MT
Goldman Sachs Downgrades Nektar Therapeutics to Sell from Neutral, Sets $3 Price Target	22-04-18	MT
SVB Leerink Adjusts Nektar Therapeutics' Price Target to $6 from $7, Keeps Market Perform Rating	22-04-18	MT
Mizuho Securities Adjusts Price Target on Nektar Therapeutics to $6 From $8, Maintains Neutral Rating	22-04-18	MT
Canaccord Genuity Adjusts Nektar Therapeutics' Price Target to $6 From $25, Reiterates Buy Rating	22-03-16	MT
History shows stocks can weather rate hike cycle	22-03-16	RE
SVB Leerink Adjusts Nektar Therapeutics' Price Target to $7 from $18, Keeps Market Perform Rating	22-03-15	MT
Mizuho Securities Downgrades Nektar Therapeutics to Neutral From Buy, Adjusts Price Target to $8 From $35	22-03-15	MT
Cowen Downgrades Nektar Therapeutics to Market Perform From Outperform	22-03-15	MT
Oppenheimer Downgrades Nektar Therapeutics to Market Perform From Outperform, Adjusts Price Target to $6 From $21	22-03-14	MT
BTIG Research Downgrades Nektar Therapeutics to Neutral From Buy	22-03-14	MT
William Blair Downgrades Nektar Therapeutics to Market Perform Form Outperform, Adjusts Price Target to $4.49 From $10.98	22-03-14	MT
BofA Securities Downgrades Nektar Therapeutics to Underperform from Neutral, Adjusts Price Target to $6 from $18	22-03-14	MT
Oppenheimer Upgrades Nektar Therapeutics to Outperform From Perform, Maintains $21 Price Target	22-03-09	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.35 USD

Average target price

1 USD

Spread / Average Target

-25.93%

High Price Target

1 USD

Spread / Highest target

-25.93%

Low Price Target

1 USD

Spread / Lowest Target

-25.93%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Nektar Therapeutics

Jefferies & Co.
TD Cowen
Oppenheimer
Goldman Sachs
SVB Securities LLC
JPMorgan Chase
Mizuho Securities
SVB Leerink
Canaccord Genuity
Cowen
BofA Securities
BTIG
William Blair & Co.
Benchmark Capital
Stifel Nicolaus

Ratings for Nektar Therapeutics

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar